HeartBeam has announced a strategic alliance agreement (SAA) with global tech giant Samsung. The alliance, announced today, builds upon an existing SAA between Samsung and Livmor, whose assets HeartBeam acquired earlier this year. Livmor created the FDA-cleared wearable Halo atrial fibrillation detection system — an FDA-cleared, Samsung-Galaxy-watch-based arrhythmia detection tool. Meanwhile, HeartBeam recently secured a […]
HeartBeam
HeartBeam wins AI-related patent for handheld vector ECG
HeartBeam (Nasaq:BEAT) announced today that it received a key patent relating to AI capabilities for its AIMIGo system. The U.S. Patent and Trademark Office (USPTO) issued the allowance for a patent titled “Hand Held Device for Automatic Cardiac Risk and Diagnostic Assessment.” The patent describes a system that combines recorded cardiac signals from AIMIGo with […]
HeartBeam submits AIMIGo vector ECG for FDA 510(k) clearance
HeartBeam (Nasdaq:BEAT) announced today that it submitted a 510(k) application to the FDA for its AIMIGo system. AIMIGo, a personal, portable vector electrocardiogram (VECG) system assists patients and clinicians in assessing cardiac symptoms. It utilizes a reusable, credit card-sized VECG recording device and cloud-based software. The system can deliver critical data to clinicians in real-time outside […]
HeartBeam raises $23.2M
HeartBeam (Nasdaq:BEAT) announced on Wednesday that it closed a secondary offering of common stock worth $23.2 million. Santa Clara, California-based HeartBeam offered more than 16.6 million shares of its common stock. The offering amounts to net proceeds of $23.2 million after deducting placement agent discounts, commissions and offering expenses. Public Ventures LLC acted as placement […]
HeartBeam acquires patient monitoring assets from Livmor
HeartBeam (Nasdaq:BEAT) announced today that it acquired substantially all assets from Livmor, which develops remote monitoring technology. Livmor, a digital health solutions company, provides a patient-engaging remote monitoring system for critical physiological biomarkers. HeartBeam said in a news release that the acquisition extends its reach in remote monitoring and detection. It now has full ownership […]
HeartBeam appoints new president
HeartBeam (Nasdaq:BEAT) announced today that it appointed Robert Eno to its newly created position of president. Eno’s responsibilities include the company’s strategic direction, commercialization efforts and day-to-day operations. His role includes these responsibilities over the HeartBeam AIMI and HeartBeam AIMIGo platforms. The Santa Clara, California-based company designed AIMIGo as a credit card-sized, 12-lead 3D vector […]
HeartBeam expects FDA to approve AIMI system for acute care settings in 2023
In a letter to shareholders, HeartBeam (Nasdaq:BEAT) founder and CEO Branislav Vajdic laid out potential regulatory timelines for 2023. Calling 2022 “a transformative year,” Vajdic updated the expectations for HeartBeam’s AIMIGo and AIMI systems. The company designed AIMIGo as a credit card-sized, 12-lead 3D vector electrocardiogram (ECG) device. It developed AIMI for acute care settings. […]
HeartBeam names new chief medical officer
HeartBeam (Nasdaq:BEAT) announced today that it appointed Dr. Peter Fitzgerald as its new chief medical officer (CMO). Santa Clara, California–based HeartBeam develops a 3D-vector electrocardiogram (ECG) platform for heart attack detection. The company said in a news release that Fitzgerald joins with “world-renowned” expertise in interventional cardiology. HeartBeam also referred to him as an “accomplished […]
HeartBeam enables smartwatch connectivity for heart monitoring
HeartBeam (Nasdaq:BEAT) announced today that it expanded its product portfolio to add arrhythmia detection capabilities to wearables. Santa Clara, California-based HeartBeam said in a news release that it aims to serve the growing cardiac device wearable market. The pipeline advancement allows for the addition of arrhythmia detection capabilities for AFib and other arrhythmia monitoring. The […]
HeartBeam picks up patent for 12-lead ECG patch
HeartBeam (Nasdaq:BEAT) announced today that the U.S. Patent and Trademark Office issued a patent for its 12-lead electrocardiogram (ECG) patch. Santa Clara, California–based HeartBeam designed its ECG patch monitor for detecting acute coronary syndrome (ACS) and cardiac arrhythmia. The company said in a news release that the granted patent builds on its portfolio, enabling 12-lead […]
HeartBeam submits heart attack diagnostic platform for FDA 510(k) clearance
HeartBeam (Nasdaq:BEAT) announced today that it submitted a 510(k) clearance application to the FDA for its HeartBeam AIMI platform. Santa Clara, California-based HeartBeam designed its proprietary electrocardiogram (ECG) technology for use in diagnosing heart attacks. The company’s HeartBeam AIMI platform assists healthcare professionals in identifying patients who present with chest pain to facilitate rapid detection […]
